Allarta’s Proprietary Platform

Designed to overcome immune rejection, prevent cell escape and safely deliver allogeneic cell therapies.

Platform Indications

Allarta’s lead product is a cell therapy focused on type 1 diabetes (T1D) as a first indication.

Diabetes DONOR Islet Transplants

Diabetes BETA Cell Therapy as SoC

Sensor Coatings

Rare Blood Disorders

Oncology Solid Tumors

Neurodegenerative Disorders

Lysosomal Disorders

Cardiac and Inflammatory Indications